Gilead Sciences, Inc. $GILD Shares Purchased by L2 Asset Management LLC

L2 Asset Management LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 70,920 shares of the biopharmaceutical company’s stock after acquiring an additional 10,200 shares during the period. Gilead Sciences accounts for 1.2% of L2 Asset Management LLC’s investment portfolio, making the stock its 18th biggest holding. L2 Asset Management LLC’s holdings in Gilead Sciences were worth $8,705,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Quattro Advisors LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $26,000. Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $28,000. Financial Consulate Inc. raised its stake in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 109 shares during the last quarter. North Star Investment Management Corp. raised its stake in shares of Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 86 shares during the last quarter. Finally, BOCHK Asset Management Ltd acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $31,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on GILD shares. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 20th. Rothschild & Co Redburn decreased their price objective on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Gilead Sciences in a report on Tuesday, June 9th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Finally, Daiwa Securities Group decreased their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $156.93.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. This trade represents a 2.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 62,000 shares of company stock worth $8,182,190 in the last ninety days. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $124.30 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $154.33 billion, a PE ratio of 16.93 and a beta of 0.31. The stock’s 50-day moving average price is $132.86 and its 200-day moving average price is $134.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same period last year, the firm earned $1.81 EPS. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.